Healing Touch During Chemotherapy Infusions for Women With Breast Cancer

This study is currently recruiting participants.

Verified by Stanford University, August 2009

First Received: September 20, 2007 Last Updated: August 21, 2009 History of Changes

Sponsored by:	Stanford University
Information provided by:	Stanford University
ClinicalTrials.gov Identifier:	NCT00533663

Purpose

To study the effectiveness of Healing Touch provided during chemotherapy infusions on the experience of women undergoing treatment for breast cancer. Healing Touch (HT) is a gentle, non-invasive form of energy-balancing work that promotes relaxation and can help manage the side effects of chemotherapy.

Condition	Intervention
Breast Cancer	Procedure: Healing Touch

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Factorial Assignment, Efficacy Study
Official Title:	Healing Touch During Chemotherapy Infusions for Women With Breast Cancer

Resource links provided by NLM:

Genetics Home Reference related topics: breast cancer

MedlinePlus related topics: Breast Cancer Cancer

U.S. FDA Resources

Further study details as provided by Stanford University:

Primary Outcome Measures:

FACT-B summary score

Secondary Outcome Measures:

Domain scores for FACT-B; BSI-18; FACIT-Fatigue; nausea measured on a Likert scale

Estimated Enrollment:	45
Study Start Date:	April 2007
Estimated Primary Completion Date:	April 2017 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:- Stage I or II breast cancer

Post-op
On treatment protocol of eight weeks of AC given every other week followed by 8 weeks of paclitaxel given every other week
ECOG Performance Status: 0-2
Speak and read English

Exclusion Criteria:- Previous chemotherapy exposure

Concomitant energy work interventions (HT, Reiki, QiGong, acupuncture).

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00533663

Contacts

Contact: Kathy Turner

(650) 736-1802

kathyt@stanford.edu

Locations

United States, California
Stanford University School of Medicine	Recruiting
Stanford, California, United States, 94305
Contact: Kathy Turner 650-736-1802 kathyt@stanford.edu
Contact: Cancer Clinical Trials Office (650) 498-7061
Principal Investigator: Dr. Ellie Guardino MD/PhD
Principal Investigator: Kathy Turner RN, NP

Sponsors and Collaborators

Stanford University

Investigators

Principal Investigator:	Dr. Ellie Guardino MD/PhD	Stanford University
Principal Investigator:	Kathy Turner RN, NP	Stanford University

More Information

No publications provided

Responsible Party:	Stanford University School of Medicine ( Kathy Turner RN, NP, Principal Investigator )
Study ID Numbers:	BRSADJ0007, 7696, BRSADJ0007, NCT00533663
Study First Received:	September 20, 2007
Last Updated:	August 21, 2009
ClinicalTrials.gov Identifier:	NCT00533663 History of Changes
Health Authority:	United States: Food and Drug Administration; United States: Institutional Review Board

Study placed in the following topic categories:

Skin Diseases
Breast Neoplasms
Breast Diseases

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site
Skin Diseases
Breast Neoplasms
Breast Diseases

ClinicalTrials.gov processed this record on September 10, 2009